Session: 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Poster II
Hematology Disease Topics & Pathways:
Diseases, Genetic Disorders
Methods: In order to understand the molecular basis for polycythemia of high altitude, we have generated a disease in-the dish-model by re-programming fibroblasts and native CD34+ve cells from CMS and non-CMS subjects and converting them to RBC. Using this in-vitro platform, we are now studying the interactions between genetic factors and sex hormones (Testosterone, Estrogen and Progesterone) and their effect on RBC production in the CMS and non-CMS subjects at high altitude.
Results: While we found that testosterone increased RBC production mildly (insignificantly), estrogen in physiologic concentrations (10nM), in sharp contrast, reduced the CD235a (Glycophorin A- marker of mature RBC) remarkably (from 56% in the untreated CMS sample to 10% in the treated CMS) and eliminated the CMS EE phenotype. There is also stage-specificity and dose response effects for estrogen. This strongly suggests that estrogen has a protective role against the polycythemia phenotype. To probe further, we studied the effect of estrogen (10nM) on GATA1, a critical link with erythropoiesis. There was a sharp 5 fold decrease in GATA1 (p<0.01) and its target genes such as Alas2 (p<0.001) in erythroid cells. This decreased expression resulted in marked reduction (>50%) in RBC production, demonstrating that estrogen constrains RBC production in females.
Conclusion: Our results demonstrate that estrogen inhibits GATA1 expression and prevents excessive erythropoiesis and Monge’s disease in females at high altitude. We believe that these studies not only shed light on the role of sex hormones on hypoxia-induced excessive erythropoiesis but have a broader application in their regulation of erythropoiesis and related blood disorders.
Disclosures: No relevant conflicts of interest to declare.
See more of: Oral and Poster Abstracts